ClinicalTrials.gg
CompletedNCT01340768Updated Jun 5, 2017Results posted

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

A Phase 3 interventional study of Sitagliptin and Sulfonylurea in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2010, registered Mar 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
870
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
12th of 197
870 · median 102
Started
2010
with 22 others
Phase 3
74 of 198
none open now
Registered
99th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 74 in phase 3, and was the 99th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast during the month of Ramadan. The primary hypothesis is that during the 30 days of Ramadan fasting, treatment with sitagliptin (with or without metformin) compared to SU treatment (with or without metformin) results in a lower incidence of hypoglycemia in participants with T2DM.

Read the detailed description

This study and NCT01131182 (MK-0431-263) have the same design but are conducted under separate protocols, in different countries, according to local guidelines.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Glucose metabolism disorders Metabolic diseases Peptidase inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Muslim, with type 2 diabetes mellitus
  • Intends to fast during the month of Ramadan
  • (HbA1c) ≤10% at screening
  • On a stable dose of a SU drug (glibenclamide, glimepiride, or gliclazide), for at least three months, with or without metformin therapy at a stable dose

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Pregnant or breast feeding or with gestational diabetes
  • or to dipeptidyl peptidase-4 (DPP-4) treatment
  • Serum creatinine ≥1.5 mg/dL (males), ≥1.4 mg/dL (females)
  • History of severe hypoglycemia (defined as a hypoglycemic event requiring the assistance of another individual, and/or resulting in a emergency department admission, physician office visit and/or hospitalization)
  • Any use of insulin (prior to or during Ramadan)
  • Use of any class of oral antidiabetic therapy other than an SU or metformin
  • Current participation in another interventional study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
870 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin 100mg taken orally once daily with or without metformin

    Drug: Sitagliptin · Drug: Metformin

  • Active comparator
    Sulfonylurea Therapy

    Usual sulfonylurea therapy with or without metformin

    Drug: Sulfonylurea · Drug: Metformin

Interventions

  • One 100 mg tablet taken orally once daily

    Also known as: Sitagliptin phosphate, MK-0431, JANUVIA®

  • DrugSulfonylurea

    Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea

    Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.

    Also known as: Amaryl (glimepiride)

  • Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Symptomatic Hypoglycemic Event

    Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example, but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change).

    Time frame: Up to 30 days (Day 1 through last day of Ramadan)

Secondary outcomes

  1. Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event

    Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change). Asymptomatic hypoglycemic events were based on self-monitored finger-stick blood glucose level.

    Time frame: Up to 30 days (Day 1 through last day of Ramadan)

07

Results

Posted Oct 8, 2012

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinSulfonylurea Therapy
Started436434
Completed419429
Not completed175
Withdrew: Lost to follow-up104
Withdrew: Withdrawal by subject51
Withdrew: Other20

Outcome measures

PrimaryPercentage of Participants With at Least One Symptomatic Hypoglycemic Event

Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example, but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change).

Time frame:
Up to 30 days (Day 1 through last day of Ramadan)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Symptomatic Hypoglycemic Event
percentage of participantsSitagliptinSulfonylurea Therapy
Percentage of Participants With at Least One Symptomatic Hypoglycemic Event3.87.3
Statistical analysis
  • Sitagliptin vs Sulfonylurea Therapy · Cochran-Mantel-Haenszel · p = 0.028 (P-value for association between treatment groups and proportions controlling for prior therapy (monotherapy or combination therapy).) · Risk ratio (rr): 0.52 · 95% CI 0.29 to 0.94
SecondaryPercentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event

Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change). Asymptomatic hypoglycemic events were based on self-monitored finger-stick blood glucose level.

Time frame:
Up to 30 days (Day 1 through last day of Ramadan)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event
percentage of participantsSitagliptinSulfonylurea Therapy
Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event4.89.6
Statistical analysis
  • Sitagliptin vs Sulfonylurea Therapy · Cochran-Mantel-Haenszel · p = 0.006 (P-value for association between treatment groups and proportions controlling for prior therapy (monotherapy or combination therapy).) · Risk ratio (rr): 0.49 · 95% CI 0.29 to 0.83

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—1/421 (0.2%)16/421 (3.8%)
Sulfonylurea Therapy—0/427 (0%)33/427 (7.7%)
Most frequent serious events
Most frequent serious events
EventSitagliptinSulfonylurea Therapy
Road traffic accidentInjury, poisoning and procedural complications1/4210/427
Most frequent other events
Most frequent other events
EventSitagliptinSulfonylurea Therapy
HypoglycemiaMetabolism and nutrition disorders16/42133/427

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinSulfonylurea TherapyTotal
Mean51.4 (26 to 80)50.7 (23 to 78)51.0 (23 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinSulfonylurea TherapyTotal
Female213233446
Male208194402
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, Suryawanshi S, Davies MJ, Girman CJ, Katzeff HL, Radican L, Engel SS, Wolthers T. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012 Aug;28(8):1289-96. doi: 10.1185/03007995.2012.707119. Epub 2012 Jul 6. PubMed 22738801 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Sep 2011, 14 months.

Results were first posted in Oct 2012, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2011
First posted
Apr 25, 2011
StartActual
Jun 22, 2010
Primary completionActual
Sep 21, 2011
CompletionActual
Sep 21, 2011
Results first posted
Oct 8, 2012
Last update
Jun 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01340768
Responsible party
Sponsor
First posted
Apr 25, 2011
Start date
Jun 22, 2010
Primary completion
Sep 21, 2011
Completion
Sep 21, 2011
Results posted
Oct 8, 2012
Last update
Jun 5, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion